Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 43, Issue 2, 2016, Pages 374-385

  Morris, Elizabeth ^a   Chalkidou, Anastasia ^a   Hammers, Alexander ^a   Peacock, Janet ^a,b,c   Summers, Jennifer ^a,b,c   Keevil, Stephen ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c BHF Centre for Regenerative Medicine and BHF Centre of Excellence and the Biomedical Research Centre at Guy s St Thomas NHS Foundation Trust and King s College London   (United Kingdom)

Author keywords

Alzheimer s disease; Amyloid; Florbetaben; Florbetapir; Flutemetamol; PET

Indexed keywords

AMYLOID F 18; TRACER; UNCLASSIFIED DRUG; 4-(N-METHYLAMINO)-4'-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; ANILINE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; FLUTEMETAMOL; RADIOPHARMACEUTICAL AGENT; STILBENE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL PATHWAY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; AGED; CASE CONTROL STUDY; DIAGNOSTIC IMAGING; EVALUATION STUDY; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; STANDARDS;

AGED; ALZHEIMER DISEASE; ANILINE COMPOUNDS; BENZOTHIAZOLES; CASE-CONTROL STUDIES; ETHYLENE GLYCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; STILBENES;

EID: 84952987419     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3228-x     Document Type: Article

References (48)

1. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29.
2. Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3:111cm33. doi:10.1126/scitranslmed.3002609.
3. Cummings JL. Alzheimer’s disease. N Engl J Med. 2004;351:56–67.
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–44.
5. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143–53.
6. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–9. doi:10.1016/j.jalz.2011.03.005.
7. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69:1471–84.
8. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306–19. doi:10.1002/ana.20009.
9. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528–47.
10. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557–68.
11. Hatashita S, Yamasaki H. Clinically different stages of Alzheimer’s disease associated by amyloid deposition with 11C-PIB PET imaging. J Alzheimers Dis. 2010;21:995–1003. doi:10.3233/JAD-2010-100222.
12. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131:1630–45. doi:10.1093/brain/awn016.
13. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431–4. doi:10.1001/archneur.64.3.431.
14. Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease. Eur J Nucl Med. 2014;41:290–300.
15. European Medicines Agency. Amyvid: florbetapir (18F). Authorisation details. 1999. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002422/human_med_001611.jsp&mid=WC0b01ac058001d124. Accessed 22 Oct 2015.
16. European Medicines Agency. Neuraceq: florbetaben (18F). Authorisation details. 1999. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002553/human_med_001716.jsp&mid=WC0b01ac058001d124. Accessed 22 Oct 2015.
17. European Medicines Agency. Vizamyl: flutemetamol (18F). Authorisation details. 1999. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002557/human_med_001794.jsp&mid=WC0b01ac058001d124. Accessed 22 Oct 2015.
18. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35.
19. Camus V, Payoux P, Barre L, Desgranges B, Voisin T, Tauber C, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med. 2012;39:621–31.
20. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78.
21. Huang KL, Lin KJ, Hsiao IT, Kuo HC, Hsu WC, Chuang WL, et al. Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer’s disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. PLoS One. 2013;8;e58974.
22. Newberg AB, Arnold SE, Wintering N, Rovner BW, Alavi A. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med. 2012;53:902–7.
23. Siderowf A, Pontecorvo M, Shill H, Mintun M, Arora A, Joshi A, et al. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders. BMC Neurol. 2014;14:79.
24. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.
25. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210–7.
26. Whiting P, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
27. Whiting P, Weswood M, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6:9.
28. Leeflang MM, Deeks JJ, Takwoingi Y, Macaskill P. Cochrane diagnostic test accuracy reviews. Syst Rev. 2013;2:82.
29. Chalkidou A, Landau DB, Odell EW, Cornelius VR, O'Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2012;48:3499–513. doi:10.1016/j.ejca.2012.05.001.
30. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM; Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889–97. doi:10.7326/0003-4819-149-12-200812160-00008.
31. Whiting P, Harbord R, Kleijnen J. No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med Res Methodol. 2005;5:19.
32. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi:10.1136/bmj.b2700.
33. Raniga P, Bourgeat P, Fripp J, Acosta O, Villemagne VL, Rowe C, et al. Automated 11C-PiB standardized uptake value ratio. Acad Radiol. 2008;15:1376–89. doi:10.1016/j.acra.2008.07.006.
34. Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. BMJ. 1994;309:188.
35. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829–35.
36. Ikari Y, Nishio T, Makishi Y, Miya Y, Ito K, Koeppe RA, et al. Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer's disease neuroimaging initiative (J-ADNI) multi-center study. Ann Nucl Med. 2012;26:535–44. doi:10.1007/s12149-012-0605-4.
37. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519–27.
38. Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. Am J Neuroradiol. 2013;34:944–50, S1–S11. doi:10.3174/ajnr.A3324.
39. Richards D, Sabbagh MN. Florbetaben for PET imaging of beta-amyloid plaques in the brain. Neurol Ther. 2014;3:79–88.
40. Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11:1050–68.
41. Heckemann RA, Hajnal JV, Aljabar P, Rueckert D, Hammers A. Automatic anatomical brain MRI segmentation combining label propagation and decision fusion. Neuroimage. 2006;33:115–26. doi:10.1016/j.neuroimage.2006.05.061.
42. Svedberg MM, Hall H, Hellström-Lindahl E, Estrada S, Guan Z, Nordberg A, et al. [11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients. Neurochem Int. 2009;54:347–57. doi:10.1016/j.neuint.2008.12.016.
43. Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, et al. 11 C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2014;7:CD010386. doi:10.1002/14651858.CD010386.pub2.
44. Mitchell AJ. A meta-analysis of the accuracy of the Mini-Mental State Examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res. 2009;43:411–31. doi:10.1016/j.jpsychires.2008.04.014.
45. Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis. 2011;26:627–45.
46. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–46.
47. Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC, Frisoni GB, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol. 2012;19:1487–501. doi:10.1111/j.1468-1331.2012.03859.x.
48. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med. 2013;54:476–90.